Spire Healthcare board reshuffle as £1bn private takeover closes

Spire Healthcare announced on Friday that its chief executive Justin Ash will retire and chairman Sir Ian Cheshire will step down as the London‑listed group is bought for £1.03bn by a new vehicle, Tulip UK Bidco. The consortium behind the bid includes British investment firm Toscafund, UK private‑equity house THCP Advisory and California‑based manager Ares. Sir David Sloman will serve as interim chief executive and former Co‑op chair Debbie White will take over as interim chair.

Deal terms and market reaction

The offer values each share at 250p, a 66 per cent premium to the price at the start of May when Toscafund first approached the board. Shares closed at 242p on Friday, up 15 per cent from their July 2014 IPO level, and had more than doubled after the initial approach was disclosed.

The board said the decision was driven by concerns that the share price could enter a period of volatility that would not reflect the company’s growth prospects. Ongoing macro‑economic uncertainty and cost pressures were also cited as reasons to accept a firm offer now.

Background and broader context

Spire operates 38 private hospitals and 55 clinics across the UK, treating more than 1.36 million patients in 2025. A strategic review led by advisory firm Rothschild examined over 60 potential suitors before the consortium emerged as the only party to submit a formally attractive proposal.

The transaction adds to a flurry of private‑equity interest in publicly listed UK firms. Earlier this week, three FTSE‑100 constituents, Bodycote, Gamma Communications and Capricorn, disclosed that they were entertaining offers worth more than £3bn, putting further pressure on the London Stock Exchange’s public market dynamics. Broader UK growth concerns have heightened scrutiny of companies that rely heavily on debt‑financed expansion.

“Under [Ash’s] leadership, Spire Healthcare has evolved from a hospital‑only business into a leading integrated healthcare company,” said Debbie White.

What comes next

With the deal expected to close later this year, Spire will likely be delisted and placed under the private ownership of Tulip UK Bidco. The new board has signalled an intention to review the group’s asset base, potentially repurposing or selling freehold properties to fund further expansion or technology upgrades.

Investors who remain in the public market will watch closely for any ripple effects on other UK healthcare providers and on the broader trend of privatisations that could reshape the London market’s composition.